ORIENT BIO Inc. Logo

ORIENT BIO Inc.

002630.KS

(1.2)
Stock Price

465,00 KRW

-12.82% ROA

3.27% ROE

-7.56x PER

Market Cap.

72.563.690.052,00 KRW

0.41% DER

0% Yield

8.67% NPM

ORIENT BIO Inc. Stock Analysis

ORIENT BIO Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

ORIENT BIO Inc. Fundamental Stock Analysis
# Analysis Rating
1 PBV

The stock's low PBV ratio (0.98x) suggests it's undervalued, making it an attractive opportunity for investors.

2 DER

The stock has a low debt to equity ratio (10%), which means it has a small amount of debt compared to the ownership it holds

3 Graham Number

Based on the Graham number, this company's stock price appears to be lower than its intrinsic value, signaling a potentially favorable investment choice.

4 ROE

The stock's ROE indicates a negative return (-29.83%) on shareholders' equity, suggesting poor financial performance.

5 ROA

The stock's ROA (-24.34%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

6 Revenue Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

7 Net Profit Growth

This company's net profit has remained stagnant over the past five years, indicating a lack of growth and making it a less favorable investment option.

8 Assets Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

9 Dividend Growth

The company's dividend growth has shown no improvement in the past three years, making it a less attractive investment option for those seeking increasing returns.

10 Dividend

The company has not distributed any dividends in the past three years, which may raise concerns for investors looking for regular income from their investments.

11 Buffet Intrinsic Value

The company's stock shows signs of being overvalued (-973) according to Warren Buffett's formula, indicating a potential downside as its market price exceeds its estimated intrinsic value.

ORIENT BIO Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

ORIENT BIO Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Hold
4 Stoch RSI Hold

ORIENT BIO Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

ORIENT BIO Inc. Revenue
Year Revenue Growth
2006 22.451.710.000
2007 43.857.141.000 48.81%
2008 42.803.189.000 -2.46%
2009 44.736.561.000 4.32%
2010 48.171.311.000 7.13%
2011 52.052.582.020 7.46%
2012 76.980.372.440 32.38%
2013 83.722.281.280 8.05%
2014 93.709.381.140 10.66%
2015 105.049.545.520 10.8%
2016 109.019.002.320 3.64%
2017 121.207.763.260 10.06%
2018 30.373.353.890 -299.06%
2019 37.699.312.900 19.43%
2020 52.020.405.170 27.53%
2021 26.276.462.480 -97.97%
2022 28.819.028.140 8.82%
2023 25.642.763.040 -12.39%
2023 28.819.030.000 11.02%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

ORIENT BIO Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2006 30.793.000
2007 1.216.130.000 97.47%
2008 1.346.630.000 9.69%
2009 1.482.847.000 9.19%
2010 1.405.299.000 -5.52%
2011 1.604.452.000 12.41%
2012 704.077.100 -127.88%
2013 426.193.090 -65.2%
2014 551.161.880 22.67%
2015 576.227.480 4.35%
2016 1.162.560.440 50.43%
2017 2.000.177.500 41.88%
2018 655.277.810 -205.24%
2019 1.406.216.470 53.4%
2020 2.645.272.740 46.84%
2021 2.594.946.240 -1.94%
2022 1.801.325.100 -44.06%
2023 4.443.317.520 59.46%
2023 1.801.330.000 -146.67%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

ORIENT BIO Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2006 723.350.000
2007 874.716.000 17.3%
2008 962.416.000 9.11%
2009 830.118.000 -15.94%
2010 998.866.000 16.89%
2011 1.269.324.000 21.31%
2012 1.178.432.550 -7.71%
2013 1.168.709.140 -0.83%
2014 1.702.090.340 31.34%
2015 1.830.226.220 7%
2016 1.749.539.980 -4.61%
2017 1.956.952.300 10.6%
2018 4.447.872.810 56%
2019 3.058.414.670 -45.43%
2020 1.306.393.680 -134.11%
2021 618.535.980 -111.21%
2022 669.968.560 7.68%
2023 874.022.520 23.35%
2023 697.599.060 -25.29%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

ORIENT BIO Inc. EBITDA
Year EBITDA Growth
2006 3.407.541.000
2007 7.185.157.000 52.58%
2008 5.699.055.000 -26.08%
2009 -7.860.827.000 172.5%
2010 1.085.511.000 824.16%
2011 -1.898.944.630 157.16%
2012 7.102.371.010 126.74%
2013 1.391.673.990 -410.35%
2014 7.760.132.210 82.07%
2015 8.160.994.880 4.91%
2016 -4.887.196.750 266.99%
2017 -561.861.840 -769.82%
2018 -2.222.900.820 74.72%
2019 -4.575.208.950 51.41%
2020 2.767.315.980 265.33%
2021 1.624.103.340 -70.39%
2022 6.612.782.100 75.44%
2023 4.900.837.200 -34.93%
2023 -370.660.000 1422.19%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

ORIENT BIO Inc. Gross Profit
Year Gross Profit Growth
2006 7.827.288.000
2007 14.248.165.000 45.06%
2008 12.401.333.000 -14.89%
2009 11.749.208.000 -5.55%
2010 10.098.262.000 -16.35%
2011 14.621.697.180 30.94%
2012 17.750.690.210 17.63%
2013 13.240.087.770 -34.07%
2014 16.547.475.130 19.99%
2015 16.085.491.520 -2.87%
2016 8.370.938.180 -92.16%
2017 14.924.624.350 43.91%
2018 3.010.797.420 -395.7%
2019 7.199.572.070 58.18%
2020 19.227.505.370 62.56%
2021 9.013.569.140 -113.32%
2022 9.824.443.650 8.25%
2023 11.144.336.840 11.84%
2023 9.824.450.000 -13.43%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

ORIENT BIO Inc. Net Profit
Year Net Profit Growth
2006 526.732.000
2007 -4.556.272.000 111.56%
2008 -622.871.000 -631.5%
2009 -579.886.000 -7.41%
2010 4.066.486.000 114.26%
2011 -10.601.938.550 138.36%
2012 878.817.260 1306.39%
2013 -9.550.821.260 109.2%
2014 -1.749.195.210 -446.01%
2015 -3.009.261.090 41.87%
2016 -19.126.520.540 84.27%
2017 -13.865.151.000 -37.95%
2018 -19.505.949.560 28.92%
2019 -10.880.761.690 -79.27%
2020 -15.633.538.120 30.4%
2021 34.198.169.000 145.71%
2022 -12.423.707.810 375.27%
2023 -2.599.990.200 -377.84%
2023 8.410.922.000 130.91%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

ORIENT BIO Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2006 9
2007 -74 110.81%
2008 -7 -957.14%
2009 -6 -40%
2010 41 112.2%
2011 -107 138.32%
2012 7 1883.33%
2013 -89 106.74%
2014 -15 -535.71%
2015 -46 68.89%
2016 -117 61.21%
2017 -83 -41.46%
2018 -251 67.33%
2019 -105 -139.05%
2020 -138 23.91%
2021 -13 -961.54%
2022 -105 87.5%
2023 -20 -420%
2023 71 128.57%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

ORIENT BIO Inc. Free Cashflow
Year Free Cashflow Growth
2006 -11.513.108.000
2007 -9.641.369.000 -19.41%
2008 -10.805.123.000 10.77%
2009 4.367.171.000 347.42%
2010 -1.778.831.000 345.51%
2011 -9.712.129.200 81.68%
2012 -15.821.940.380 38.62%
2013 -10.063.437.390 -57.22%
2014 -5.671.356.550 -77.44%
2015 -15.980.091.090 64.51%
2016 -11.703.808.890 -36.54%
2017 -5.559.085.340 -110.53%
2018 -29.969.877.840 81.45%
2019 -6.554.761.040 -357.22%
2020 8.483.327.740 177.27%
2021 140.526.160 -5936.83%
2022 674.295.890 79.16%
2023 -937.769.310 171.9%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

ORIENT BIO Inc. Operating Cashflow
Year Operating Cashflow Growth
2006 1.517.804.000
2007 -5.356.962.000 128.33%
2008 -1.859.896.000 -188.02%
2009 9.351.273.000 119.89%
2010 3.114.785.000 -200.22%
2011 -7.867.483.200 139.59%
2012 5.094.251.360 254.44%
2013 2.169.073.360 -134.86%
2014 1.603.027.680 -35.31%
2015 912.429.000 -75.69%
2016 -4.652.575.000 119.61%
2017 -1.966.434.150 -136.6%
2018 -11.539.791.130 82.96%
2019 -4.671.820.920 -147.01%
2020 8.739.490.650 153.46%
2021 2.351.249.000 -271.7%
2022 1.159.936.960 -102.7%
2023 -830.769.310 239.62%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

ORIENT BIO Inc. Capital Expenditure
Year Capital Expenditure Growth
2006 13.030.912.000
2007 4.284.407.000 -204.15%
2008 8.945.227.000 52.1%
2009 4.984.102.000 -79.48%
2010 4.893.616.000 -1.85%
2011 1.844.646.000 -165.29%
2012 20.916.191.740 91.18%
2013 12.232.510.750 -70.99%
2014 7.274.384.230 -68.16%
2015 16.892.520.090 56.94%
2016 7.051.233.890 -139.57%
2017 3.592.651.190 -96.27%
2018 18.430.086.710 80.51%
2019 1.882.940.120 -878.79%
2020 256.162.910 -635.06%
2021 2.210.722.840 88.41%
2022 485.641.070 -355.22%
2023 107.000.000 -353.87%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

ORIENT BIO Inc. Equity
Year Equity Growth
2006 44.862.349.000
2007 35.202.430.000 -27.44%
2008 54.830.984.000 35.8%
2009 54.251.707.000 -1.07%
2010 58.094.160.000 6.61%
2011 52.175.836.600 -11.34%
2012 54.767.635.590 4.73%
2013 55.009.236.750 0.44%
2014 53.719.471.470 -2.4%
2015 76.855.486.880 30.1%
2016 70.301.656.950 -9.32%
2017 79.923.476.640 12.04%
2018 62.646.390.330 -27.58%
2019 51.962.960.030 -20.56%
2020 48.545.215.620 -7.04%
2021 83.188.009.900 41.64%
2022 71.392.357.780 -16.52%
2023 73.315.310.910 2.62%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

ORIENT BIO Inc. Assets
Year Assets Growth
2006 72.880.857.000
2007 82.719.151.000 11.89%
2008 98.179.231.000 15.75%
2009 104.313.844.000 5.88%
2010 84.864.177.000 -22.92%
2011 123.547.143.610 31.31%
2012 136.244.514.570 9.32%
2013 139.630.720.800 2.43%
2014 148.764.894.270 6.14%
2015 175.642.242.600 15.3%
2016 172.626.052.620 -1.75%
2017 190.030.912.920 9.16%
2018 84.088.996.360 -125.99%
2019 72.105.395.020 -16.62%
2020 71.518.505.220 -0.82%
2021 104.952.008.520 31.86%
2022 81.050.220.060 -29.49%
2023 82.327.212.020 1.55%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

ORIENT BIO Inc. Liabilities
Year Liabilities Growth
2006 28.018.508.000
2007 44.932.610.000 37.64%
2008 40.581.285.000 -10.72%
2009 42.548.636.000 4.62%
2010 19.375.681.000 -119.6%
2011 63.032.302.010 69.26%
2012 73.954.971.730 14.77%
2013 77.784.689.380 4.92%
2014 81.415.072.030 4.46%
2015 84.352.075.030 3.48%
2016 74.681.088.340 -12.95%
2017 110.107.436.280 32.17%
2018 21.442.606.030 -413.5%
2019 20.142.434.990 -6.45%
2020 22.973.289.610 12.32%
2021 21.764.271.010 -5.56%
2022 9.657.861.930 -125.35%
2023 9.011.900.150 -7.17%

ORIENT BIO Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
211.24
Net Income per Share
-80.94
Price to Earning Ratio
-7.56x
Price To Sales Ratio
2.64x
POCF Ratio
25.93
PFCF Ratio
28.04
Price to Book Ratio
1.09
EV to Sales
2.55
EV Over EBITDA
16.72
EV to Operating CashFlow
22.87
EV to FreeCashFlow
27.11
Earnings Yield
-0.13
FreeCashFlow Yield
0.04
Market Cap
72,56 Bil.
Enterprise Value
70,15 Bil.
Graham Number
1013.43
Graham NetNet
348.79

Income Statement Metrics

Net Income per Share
-80.94
Income Quality
-0.29
ROE
-0.15
Return On Assets
0.03
Return On Capital Employed
0.01
Net Income per EBT
1.1
EBT Per Ebit
4.22
Ebit per Revenue
0.02
Effective Tax Rate
-0.1

Margins

Sales, General, & Administrative to Revenue
0.03
Research & Developement to Revenue
0.09
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.36
Operating Profit Margin
0.02
Pretax Profit Margin
0.08
Net Profit Margin
0.09

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
23.6
Free CashFlow per Share
19.9
Capex to Operating CashFlow
-0.16
Capex to Revenue
-0.02
Capex to Depreciation
-0.16
Return on Invested Capital
0.02
Return on Tangible Assets
-0.13
Days Sales Outstanding
356.78
Days Payables Outstanding
10.57
Days of Inventory on Hand
117.03
Receivables Turnover
1.02
Payables Turnover
34.54
Inventory Turnover
3.12
Capex per Share
-3.69

Balance Sheet

Cash per Share
241,59
Book Value per Share
563,97
Tangible Book Value per Share
561.85
Shareholders Equity per Share
563.97
Interest Debt per Share
2.87
Debt to Equity
0
Debt to Assets
0
Net Debt to EBITDA
-0.58
Current Ratio
18.29
Tangible Asset Value
73,04 Bil.
Net Current Asset Value
47,70 Bil.
Invested Capital
0
Working Capital
53,61 Bil.
Intangibles to Total Assets
0
Average Receivables
22,86 Bil.
Average Payables
0,48 Bil.
Average Inventory
5642911775
Debt to Market Cap
0

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

ORIENT BIO Inc. Dividends
Year Dividends Growth

ORIENT BIO Inc. Profile

About ORIENT BIO Inc.

ORIENT BIO Inc. operates in the bio-industry in South Korea. The company produces laboratory animals. In addition, it offers various equipment for research environment. The company was formerly known as Orient Co., Ltd. and changed its name to ORIENT BIO Inc. in 2005. ORIENT BIO Inc. was founded in 1959 and is based in Seongnam, South Korea.

CEO
Mr. Jae-Jin Chang
Employee
125
Address
322, Galmachi-ro
Seongnam-si,

ORIENT BIO Inc. Executives & BODs

ORIENT BIO Inc. Executives & BODs
# Name Age
1 Mr. Jae-Jin Chang
Chairperson, President and Chief Executive Officer
70

ORIENT BIO Inc. Competitors